Curative Biotechnology, Inc. Share Price Other OTC

Curative Biotechnology, Inc. is a development stage biomedical company focused on therapies for rare diseases. The Company is identifying, acquiring, and developing disease modifying therapeutic drug candidates with a concentration on rare disease indications. It has ongoing programs in three different therapeutic areas: degenerative eye disease, infectious disease, and neuro oncology. It is focused on its degenerative eye disease platform. The first therapeutic to be developed on this platform is a Metformin Reformulation targeting the treatment of intermediate and late-stage age-related macular degeneration (AMD) disease. Its pipeline products include IMT504, CURB906, Metformin Reformulation, and COVID Vaccine with IMT504 Adjuvant. IMT504 is an immunotherapy for late-stage symptomatic rabies. CURB906 is a humanized CD56 monoclonal antibody carrying a cytotoxic drug conjugate directly to the tumor cancer site to kill the tumor by inhibiting tumor growth and migration of the tumor.